Singmed Participated in the 5th CMC-China 2023

At 8 a.m. on August 3rd, all the participants of Singmed arrived at the booth to arrange the exhibition, and after the entrance of the exhibition audience, we had in-depth exchanges with all guests and industry colleagues and jointly discussed cooperation opportunities.

During the conference, Mr. Albert Zhao, founder and executive director of Singmed, shared the experience, inspiration and achievements of Singmed from its initial development to today's scale in the past few years - "The Best Practice of Inhalation Spray Device Development" :

Singmed's vision: to use the technological innovation of Medical devices to empower the clinical efficacy of drug delivery and develop patient-centered drug-device combination products.

Singmed focuses on the three core drug delivery areas of pulmonary drug delivery, nasal drug delivery and ophthalmic drug delivery, concentrating on innovative design and manufacturing of drug delivery devices, so that optimized atomizing delivery can bring better drug treatment effects, provides customers with obvious clinical advantages of drug delivery device solutions, and utilizes drug delivery mechanism innovation to develop new combination products (improved new drugs), bringing patients a better life.

In addition, Mr. Albert Zhao also shared his insights on the production and development of DPI. He emphasized that scientific project management process is an inevitable condition for achieving excellent drug delivery device development results, there is no shortcut, and it is not only results-oriented, but the correct result incurred by scientific and rigorous research and development engineering management process. Enterprises should take the management of all stages of the project seriously and standardize all aspects from research and development to production. The manufacturing of SMI parts is the miracle of industry precision, there is no fast and economy, we must adhere to long-term doctrine and strengthen professionalism.

In the sharing, Mr. Albert Zhao also mentioned the competitive advantages of Singmed and introduced several star products:

The whole process of R&D design, scale manufacturing and supply chain management meets ISO-13485 medical device design and manufacturing standards, and Singmed's inhalation drug delivery devices also fully meet the relevant inhalation drug delivery product evaluation guidelines issued by the US FDA.

Suzhou Singmed has cooperated with Chinese leading listed biopharmaceutical companies to commercialize the development and manufacture of inhalation and nasal drug delivery devices for many years, including multi-dose blister DPI devices, single-dose capsule DPI devices, soft mist inhaler (SMI) devices and nasal spray devices.